07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , May 23, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/20 clsArbutus Biopharma Corp. (NASDAQ:ABUS)Chardan CapitalMadhu KumarNewSell-6%$4.08 Kumar initiated coverage with a $3.25 target, saying competition to Arbutus' lead asset, ARB-1467, raises hurdles ahead of 2H16 catalysts. He...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Epirus biosimilars, hematology, cancer news

Epirus will reduce headcount by 40% to reprioritize its pipeline to focus exclusively on developing biosimilars for rare diseases. The company will suspend development of its Phase III-ready lead program BOW015, a biosimilar of...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

Bioceros, Epirus deal

Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) markets Simponi and Stelara to treat autoimmune diseases. Epirus would not disclose when the company plans to begin clinical testing for the acquired biosimilars. Bioceros B.V., Utrecht,...
01:19 , Sep 10, 2015 |  BC Extra  |  Company News

Epirus nabs biosimilars in Bioceros takeout

Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) acquired biosimilars company Bioceros B.V. (Utrecht, the Netherlands) for $14.1 million in cash and stock to be paid over a one-year period. Epirus gains three preclinical candidates: BOW080, a biosimilar of...